1. Home
  2. DEI vs COAG Comparison

DEI vs COAG Comparison

Compare DEI & COAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Emmett Inc.

DEI

Douglas Emmett Inc.

HOLD

Current Price

$10.18

Market Cap

1.9B

Sector

Real Estate

ML Signal

HOLD

COAG

Hemab Therapeutics Holdings Inc. Common Stock

HOLD

Current Price

$35.72

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DEI
COAG
Founded
1971
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.9B
IPO Year
2006
2026

Fundamental Metrics

Financial Performance
Metric
DEI
COAG
Price
$10.18
$35.72
Analyst Decision
Hold
Strong Buy
Analyst Count
12
6
Target Price
$12.40
★ $62.67
AVG Volume (30 Days)
★ 2.0M
346.6K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
★ 7.47%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
★ $1,003,982,000.00
N/A
Revenue This Year
$1.79
N/A
Revenue Next Year
$2.61
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 1.77
N/A
52 Week Low
$9.04
$27.38
52 Week High
$13.32
$55.42

Technical Indicators

Market Signals
Indicator
DEI
COAG
Relative Strength Index (RSI) 53.43 54.18
Support Level $9.30 $28.46
Resistance Level $10.59 $38.87
Average True Range (ATR) 0.32 2.49
MACD 0.12 1.06
Stochastic Oscillator 88.52 90.18

Price Performance

Historical Comparison
DEI
COAG

About DEI Douglas Emmett Inc.

Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments: the office segment and multifamily segment, of which Office segment derives maximum revenue.

About COAG Hemab Therapeutics Holdings Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

Share on Social Networks: